US: New COVID variant cases surge as vaccination rate lags

A registered nurse inoculates a man with a COVID-19 vaccine at a clinic set up in the parking lot of CalOptima in Orange, California, Aug 28, 2021. (JAE C HONG / AP)

LOS ANGELES / MOSCOW / HARARE – New Omicron subvariants BQ.1 and BQ.1.1 accounted for nearly half of new COVID-19 cases in the United States in the past week, while health officials have been urging the public to take an updated booster dose.

BQ.1.1 made up nearly 24.1 percent of circulating variants in the week ending Nov 12, and BQ.1 was estimated to make up 20.1 percent, according to the latest estimates from the US Centers for Disease Control and Prevention (CDC).

The two new variants have been growing especially fast since October. At the beginning of October, each one accounted for about 1 percent of new infections in the United States, but they have been roughly doubling in prevalence each week.

READ MORE: US COVID public health emergency to stay in place

The two variants are descendants of Omicron's BA.5 subvariant and have been spreading rapidly in Europe.

The predominant Omicron lineage in the United States remains BA.5, which accounted for 29.7 percent of new infections in the latest week, CDC data showed.

The CDC is also tracking the rise of another COVID-19 variant known as BN.1, the latest new Omicron descendant now spreading around the country.

Some 4.3 percent of new COVID-19 cases nationwide are now linked to the BN.1 variant, according to CDC data. Prevalence of the new strain is largest in the West, in the region that spans Arizona, California, Hawaii, and Nevada.

A CDC official said Saturday at a webinar hosted by the Infectious Disease Society of America that BN.1 is estimated to be doubling in proportion roughly every two weeks across the country, though they cautioned that early estimates remain muddy.

ALSO READ: US FDA panel votes against Veru's COVID-19 pill

Another new variant XBB had been watched closely abroad. It has yet to reach large enough levels in the United States to be listed as a standalone strain.

The rising trend of new variants has led regulators and vaccine manufacturers to monitor more closely in case they start to evade protection offered by current vaccines.

Pedestrians walk past a signs hanging outside Pfizer headquarters in New York and one hanging at a bus stop encouraging the COVID-19 booster, May 23, 2022. (MARY ALTAFFER / AP)

In fall 2022, the CDC recommended a bivalent mRNA COVID-19 vaccine booster dose for people aged 5 years and above. The updated booster dose is administered at least 2 months after completing the primary series or after receipt of a monovalent booster dose.

"Bivalent COVID-19 vaccine booster doses might improve protection against SARS-CoV-2 Omicron sub-lineages and, along with completion of a primary series in persons who remain unvaccinated, are important to protect against COVID-19, particularly among those people who are at increased risk for severe illness and death," said the CDC.

ALSO READ: Spike in flu, RSV, COVID cases overwhelm US health facilities

The COVID-19 vaccination rate in the United States lags that of many other high-income countries.

As of Nov 9, about 31.4 million people in the United States, or 10.1 percent of the US population, have received the updated booster dose, the latest CDC data show. 

Policy unchanged

US President Joe Biden would veto a proposed US Senate resolution that would terminate a national emergency declared in 2020 in response to the COVID-19 pandemic, the White House said on Tuesday.

Republican US Senator Roger Marshall in September called for a vote to end the emergency declaration after Biden told CBS News in an interview that the pandemic was "over."

The White House later walked back Biden's comments, saying there had been no change in the administration's COVID-19 policy.

Marshall's proposed resolution was put on the Senate calendar in October but has not yet been put to a vote in the Democrat-controlled chamber.


Russia registered 4,431 new COVID-19 cases in the past 24 hours, taking the nationwide tally to 21,508,961, said the official monitoring and response center on Tuesday.

The center said the nationwide death toll increased by 64 to 391,149, while the number of recoveries grew by 6,354 to 20,912,331.

Meanwhile, Moscow reported 522 new cases, taking its total to 3,242,163.

Children wait in a line to be vaccinated at a school on the outskirts of the capital, Harare, Zimbabwe, March, 24, 2022. (TSVANGIRAYI MUKWAZHI / AP)


Zimbabwe will include the COVID-19 vaccination in the second round of its polio vaccination campaign set for early next month, a cabinet minister said Tuesday.

Addressing a post-cabinet media briefing, Sekai Nzenza, acting minister of information, publicity and broadcasting services, said the COVID-19 vaccination would tackle the recent increase in new cases of 295 last week from 179 the week before.

She said that hospital admissions had also increased to 26 last week from 13 reported the previous week.

The minister said provinces continue to prioritize COVID-19 vaccinations in all schools, focusing on the secondary schools that have not yet reached the second dose coverage target of 70 percent.

Zimbabwe conducted the first round of polio vaccination throughout the country from Oct 27-30 to protect children below the age of five following an outbreak of the disease in neighboring Malawi and Mozambique.

The second round will run from Dec 1-4.

Zimbabwe has recorded 258,643 COVID-19 cases as of Nov 13, with 252,567 recoveries and 5,610 deaths.

A total of 6,560,712 first doses of the COVID-19 vaccine have been administered, while 4,929,331 people have received their second dose and 1,215,375 their third.